Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Indicia Production Acquires Biotechnologie Appliquee

Published: Friday, March 22, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
The acquisition strengthens Indicia Production’s ability to subcontract the manufacture of ready-to-use media for microbiological testing.

Indicia Production has announced the acquisition of Biotechnologie Appliquee, based in Taden, in Cotes-d’Armor, France.

The financial terms of this buyout, completed at the end of February, have not been disclosed.

Biotechnologie Appliquee, with a turnover of EUR 500,000 in 2012 and four employees, provides contract manufacturing of ready-to-use media for microbiological testing to the food-processing, pharmaceutical and cosmetic industries.

The company is smaller and more flexible than Indicia Production with extensive expertise in subcontracting. It primarily provides low-volume manufacturing.

This acquisition therefore complements the range of mass-manufactured products from Indicia Production in Lyon.

Indicia Production can now provide contract services for both high and low volume manufacturing and can also respond to client requirements more quickly.

Indicia plans to secure new clients by expanding and diversifying its product range. The company also aims to draw on Biotechnologie Appliquee’s expertise to develop new products throughout 2013.

Ready-to-use culture media are used in the pharmaceutical industry as well as for microbiological diagnostics in food processing and environmental and water monitoring.

They are made from high-quality raw materials and use dehydrated bases selected in accordance with various standards. They are manufactured using advanced technology and are subject to quality testing by approved microbiologists.

“By joining with Indicia, we are able to expand our client base and offer a wider range of products,” said Jean-Yves Horvais, director of Biotechnologie Appliquee.

Horvais continued, “In return, Indicia brings its mass-manufacturing capacities and structured quality assurance. This will allow us to attract new companies within the industry.”

The acquisition enables Indicia Production to strengthen its position as a European leader in the manufacturing of ready-to-use media for microbiological testing.

Indicia is the first subcontractor to manufacture media pouches. The concept was developed at the site 15 years ago.

Biotechnologie Appliquee provides the newly formed company with a better understanding of the raw materials used in these media.

“With this acquisition, we hope to strengthen our production capacities and our subcontracting qualities for both high and low volume manufacturing,” said Stephane Legastelois, president and CEO of Indicia Production.

This buyout is part of Indicia Production’s growth strategy, which began in 2010, including the acquisition of new technologies to increase capacities for filling and sterilizing company media pouches.

Indicia Production, whose turnover reached EUR 5.1 million in 2012, expects a significant increase in profits over the next five years.

“The contract manufacturing market for microbiological testing and aseptic filling is booming. More industry professionals are now choosing to outsource these services in order to reduce their fixed costs,” said Stephane Legastelois. “They are also showing a keen interest in contract services, which we have just strengthened with this acquisition.”

A department manager is expected to join Indicia Production’s on-site team at Biotechnologie Appliquee, in Taden, in the second quarter of 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!